Yes, it would seem that Gilead has more interest in immunotherapies than advertised. (We know why).
Seems they have less publicized partnerships on the cheap that most are not aware of.
I have recently been looking at GRTS. Similar approach, different MOA, but definitely a "fear of CYDY" looksee imho. To date, no buyout. In their efforts to get around us, they affirm the molecule. Nothing better out there.